Screener
BridgeBio Pharma BBIO Equity Method Income
Equity Method Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Interest expense | (12,942) | (18,121) |
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
| Total other expense, net | (60,599) | (65,236) |
| Net loss | (166,555) | (169,608) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,512 | 2,186 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's equity method income?
- BridgeBio Pharma (BBIO) reported equity method income of -$18.28M in Q1 2026.
- How has BridgeBio Pharma's equity method income changed year-over-year?
- BridgeBio Pharma's equity method income decreased by 17.5% year-over-year, from -$15.56M to -$18.28M.
- What does equity method income mean?
- The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.
Ask your AI about BridgeBio Pharma's equity method income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude